Novavax, Inc. (NASDAQ: NVAX) announced the closing of the underwritten public offering priced on Thursday, June 5, 2014.The company issued 28,750,000 shares of its common stock, including 3,750,000 shares pursuant to the underwriters’ option to purchase additional shares.Novavax, Inc. (NASDAQ:NVAX) weekly performance is 7.43%. On last trading day company shares ended up $4.48. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average is 3.75%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced after the close Wednesday that it intends to offer $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement. The stock is now down 0.30 on 329K shares. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -0.47% in last trading session and ended the day on $6.38. ARIA Gross Margin is 79.20% and its return on assets is -66.50%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -21.91%.
UBS upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Neutral to Buy with a price target of $11.Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares moved down -5.27% in last trading session and was closed at $6.47, while trading in range of $6.26-$6.75. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) year to date performance is 94.88%.
The FDA had issued a partial hold on the drugs trials after a number of patients under its medications showed low-grade liver function abnormalities. The Geron Corporation (NASDAQ:GERN) was only allowed to use the drug on patients who showed significant improvement under it. The Company’s trials on two other diseases thrombocythemia and myeloma still remain under hold. Geron is thus unable to submit any clinical trial protocols in the U.S. Geron Corporation (NASDAQ:GERN) ended the last trading day at $2.98. Company weekly volatility is calculated as 13.36% and price to cash ratio as 3.22. Geron Corporation (NASDAQ:GERN) showed a positive weekly performance of 43.27%.
Returning to land, MannKind Corporation (NASDAQ:MNKD) shareholders got some good news, when RBC Capital announced it is initiating coverage of the company with an “outperform” rating in response to reports that MannKind is only six to eight weeks away from announcing a partnership to market its breakthrough Afrezza insulin inhaler.MannKind Corporation (NASDAQ:MNKD) weekly performance is 2.33%. On last trading day company shares ended up $10.57. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average is 41.92%.